Today: 29 April 2026
Credo Technology (CRDO) stock whipsaws, rebounds after CTO share-sale filing; Needham talk next
7 January 2026
1 min read

Credo Technology (CRDO) stock whipsaws, rebounds after CTO share-sale filing; Needham talk next

New York, Jan 7, 2026, 14:22 EST — Regular session

  • CRDO shares were up 6.7% after dipping about 6% earlier in the session.
  • An SEC filing showed Credo’s CTO sold shares through a family trust under a 10b5-1 plan.
  • Credo said its CEO and CFO will speak at Needham’s Growth Conference on Jan. 14.

Credo Technology Group Holding Ltd shares rebounded on Wednesday, up 6.7% at $141.80 after sliding as much as 6% earlier in the session, as investors digested an insider-sale disclosure. The stock swung between $124.85 and $143.14 in heavy midday trading.

The snapback followed two down sessions to start the week. Credo closed down 2.1% on Monday and fell another 5.2% on Tuesday, with more than 7 million shares trading each day, StockAnalysis.com data showed.

A Form 4 filed on Tuesday showed Credo chief technology officer and director Chi Fung Cheng sold 30,000 ordinary shares on Jan. 2 through the Cheng Huang Family Trust at weighted-average prices ranging from about $141.48 to $151.04. The filing said the sales were made under a Rule 10b5-1 plan — a pre-set trading program that can allow insiders to sell shares on a schedule — adopted on Sept. 5, 2025, and the trust held about 6.42 million shares after the transactions.

Credo, which sells high-speed connectivity chips and active electrical cables used in data-center networks, also flagged its next public checkpoint. The company said on Tuesday that CEO Bill Brennan and CFO Dan Fleming will present at the 28th Annual Needham Growth Conference in New York on Jan. 14 at 9:30 a.m. ET.

The wider tape offered little help in explaining the size of the move. The Nasdaq 100 tracker QQQ was up about 0.4% while the S&P 500 tracker SPY was flat; among AI-linked chip names, Nvidia rose 1.4% and Broadcom gained 1.1%, while Marvell slid 4.3% and Astera Labs added 4.2%. The VanEck Semiconductor ETF was down about 0.6%.

Investors have been leaning on the company’s last outlook as the January quarter runs down. In its Dec. 1 results release, Credo forecast third-quarter revenue of $335 million to $345 million and CEO Brennan called the prior quarter “the strongest quarterly results in Credo’s history.”

But the stock’s reliance on big customers can amplify any wobble in sentiment. Credo’s annual report said one customer accounted for 67% of fiscal 2025 revenue and the top 10 customers made up about 90%, leaving results exposed if large orders shift or slip.

Traders now look to Jan. 14 for any color on demand and whether Credo sticks to its January-quarter targets. Credo’s investor relations site lists the Needham appearance as the next scheduled event.

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Biogen lowered its 2026 adjusted earnings forecast to $14.25–$15.25 per share, citing research and development charges from recent acquisitions. First-quarter revenue rose 2% to $2.48 billion, with adjusted earnings of $3.57 per share, beating analyst estimates. Leqembi sales climbed 74% to $168 million globally.
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Micron MU stock price forecast: $400 targets collide with a $100 billion New York megafab plan
Previous Story

Micron MU stock price forecast: $400 targets collide with a $100 billion New York megafab plan

Tesla stock price forecast swings: Wall Street split from $25 to $600 ahead of earnings
Next Story

Tesla stock price forecast swings: Wall Street split from $25 to $600 ahead of earnings

Go toTop